A Phase 3 interventional study of REGN7508 and Acetylsalicylic Acid (ASA) in Symptomatic Venous Thromboembolism (VTE), sponsored by Regeneron Pharmaceuticals. Recruiting at 57 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 246 studies in Venous Thrombosis with a site in United States — 23 open to participants now, 31 under way, 5 of them phase 3. Venous Thrombosis · United States.
Among the 246 studies in Venous Thrombosis with a site in United States, this one is the 22nd largest by planned enrollment of the 184 interventional ones that give a count, is one of 5 that started in 2025, is one of 38 in phase 3, reaches primary completion later than 13 of the 30 other live ones, and was the 234th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →23 of the 246 studies in Venous Thrombosis with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Bulgaria, Japan and 2 more countries
Ages 18+
W.L.Gore & Associates · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Georgia, Japan
Ages 18+
Argon Medical Devices · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States, Australia
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
246 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 31 · Phase 3 45 · Phase 4 22
First in 1999; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 130 across the 184 interventional studies, 221 across the 60 observational. Of the 193 that completed or were terminated, 92 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 246 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 4 studies filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
13 of the studies in Venous Thrombosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04924322Phase 3Yale UniversityCatheter-Related Early Thromboprophylaxis With Enoxaparin Studies | 2027-04-30 |
| NCT07213778Phase 3Regeneron PharmaceuticalsREGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | 2027-05-17 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT06519435Mayo ClinicNon-invasive Venous Air Plethysmography Assessment of Venous Hemodynamics in Patients Suspected Deep Venous Obstruction Used in Conjunction With Intermittent Pneumatic Compression. | 2026-12 |
| NCT06451003Medical University of South CarolinaIntervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 246 studies in Venous Thrombosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery.
The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery compared to acetylsalicylic acid.
The study is looking at several other research questions, including:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/ Exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: REGN7508 · Drug: Placebo
Drug: Acetylsalicylic Acid (ASA) · Drug: Placebo
Administered per the protocol
Also known as: cenvacibart
Administered per the protocol
Administered per the protocol
Incidence of the composite endpoint of symptomatic VTE and all-cause death
Time frame: Through day 30 visit
Time to first event of the composite endpoint of symptomatic VTE and all-cause death
Time frame: Through day 30 visit
Incidence of confirmed symptomatic Deep Vein Thrombosis (DVT)
Time frame: Through day 30 visit
Incidence of confirmed Pulmonary Embolism (PE)
Time frame: Through day 30 visit
Incidence of all-cause death
Time frame: Through day 30 visit
Time to first event of the confirmed symptomatic DVT
Time frame: Through day 30 visit
Time to first event of the confirmed PE
Time frame: Through day 30 visit
Time to the all-cause death
Time frame: Through day 30 visit
Incidence of the composite endpoint of major bleeding and Clinically Relevant Non-Major (CRNM) bleeding
Time frame: Through day 30 visit
Incidence of minor bleeding
Time frame: Through day 30 visit
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Time frame: Through day 90 visit
Severity of TEAEs
Time frame: Through day 90 visit
Incidence of Anti-drug Antibody (ADA) to REGN7508
Time frame: Through day 90 visit
Magnitude of ADA to REGN7508
Time frame: Through day 90 visit
Concentrations of REGN7508
Time frame: Through day 90 visit
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for May 2027, 17 months after the start.
Of 34 phase 3 interventional studies under Venous Thrombosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 58. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cenvacibart